fluorodeoxyglucose f18 has been researched along with imatinib mesylate in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (58.18) | 29.6817 |
| 2010's | 22 (40.00) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, LC; Capdeville, R; Demetri, GD; Dimitrijevic, S; Druker, B; Joensuu, H; Roberts, PJ; Sarlomo-Rikala, M; Silberman, S; Tervahartiala, P; Tuveson, D | 1 |
| Dimitrijevic, S; Donato di Paola, E; Judson, I; Martens, M; Nielsen, OS; Sciot, R; Silberman, S; Stroobants, S; Van Glabbeke, M; van Oosterom, AT; Verweij, J; Webb, A | 1 |
| Badawi, RD; Van den Abbeele, AD | 1 |
| Chander, S; Lay Ergun, E; Shields, AF | 1 |
| Lilien, DL; Reddy, MP; Reddy, P | 1 |
| Cole, P; Dimitrijevic, S; Dumez, H; Dupont, P; Goeminne, J; Martens, M; Mortelmans, L; Nuyts, J; Sciot, R; Seegers, M; Silberman, S; Stroobants, S; van den Borne, B; van Oosterom, A | 1 |
| Berthelsen, AK; Eigtved, AI; Kinnander, C; Krarup-Hansen, A | 1 |
| Gayed, I; Iyer, R; Johnson, M; Macapinlac, H; Podoloff, D; Swanston, N; Vu, T | 1 |
| Gietema, JA; Jager, PL; van der Graaf, WT | 1 |
| Benjamin, RS; Charnsangavej, C; Choi, H; de Castro Faria, S; Johnson, MM; Macapinlac, HA; Podoloff, DA; Tamm, EP | 1 |
| Barghouth, G; Dizendorf, E; Goerres, GW; Hany, TF; Leyvraz, S; Luthi, F; Pestalozzi, B; Schnyder, P; Stupp, R; von Schulthess, GK | 1 |
| Kendler, D; Moncayo, R; Virgolini, I; Zaknun, JJ; zur Nedden, D | 1 |
| Erturk, SM | 1 |
| Ashman, LK; Binns, D; Conus, N; Cullinane, C; Dorow, DS; Hicks, RJ; Kansara, M; McArthur, GA; Thomas, DM | 1 |
| Dixon, J; Goldstein, D; Haindl, W; Rossleigh, M; Tan, BS; Walker, B | 1 |
| Camci, C; Kalender, ME; Sevinc, A; Zincirkeser, S | 1 |
| Benjamin, RS; Burgess, MA; Charnsangavej, C; Chen, LL; Choi, H; Faria, SC; Macapinlac, HA; Patel, SR; Podoloff, DA | 1 |
| Delorme, S; Fabel, M; Frank-Raue, K; Haberkorn, U; Raue, F | 1 |
| Inoue, H; Jinnouchi, S; Kukita, T; Matsumoto, T; Nakajo, M; Otsuka, M; Tanabe, H; Tateno, R | 1 |
| Guillén Ponce, C; Molina Garrido, MJ | 1 |
| Badawi, RD; Demetri, GD; Holdsworth, CH; Israel, DA; Kijewski, MF; Manola, JB; Van den Abbeele, AD | 1 |
| Abhyankar, SA; Nair, N | 1 |
| Choi, H | 1 |
| Van den Abbeele, AD | 1 |
| Baghel, NS; Dutt, A; Nair, N; Shinto, A | 1 |
| Asopa, R; Basu, S; Mohandas, KM; Peshwe, H; Vyawahare, M | 1 |
| Eslamy, HK; Quon, A | 1 |
| Benhattar, J; Delaloye, AB; Elsig, V; Guillou, L; Leyvraz, S; Luthi, F; Michielin, O; Montemurro, M; Orcurto, MV; Prior, JO; Stupp, R | 1 |
| Barzilai, M; Domachevsky, L; Peled, N | 1 |
| Dietrich, C; Hartung, E; Ignee, A | 1 |
| Antonescu, CR; Baum, CM; Bello, CL; Chen, MH; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; George, S; Heinrich, MC; Huang, X; Maki, RG; Morgan, JA; Van den Abbeele, AD | 1 |
| Gauthier, H | 1 |
| Dimitrakopoulou-Strauss, A; Hohenberger, P; Kasper, B; Strauss, LG | 1 |
| Furutani, K; Harada, M; Morita, N; Nishitani, H; Otomi, Y; Otsuka, H; Terazawa, K | 1 |
| Bruce, I; Ghosal, N; Hastings, D; Homer, J; Julyan, P; Mais, K; Ryder, WD; Shenjere, P; Slevin, NJ; Ward, T | 1 |
| Ayuso, JR; Casado, A; Cubedo, R; Del Muro, XG; Fuster, D; Lomeña, F; López-Pousa, A; Martínez-Trufero, J; Maurel, J; Pons, F; Poveda, A | 1 |
| Bellan, E; Biasco, G; Boschi, S; Castelli, M; Castellucci, P; Di Battista, M; Fanti, S; Gnocchi, C; Landuzzi, L; Lollini, PL; Nanni, C; Nannini, M; Nicoletti, G; Pantaleo, MA; Quarta, C; Rubello, D | 1 |
| Bertagna, F; Biasiotto, G; Bosio, G; Giubbini, R; Orlando, E | 1 |
| Caponigro, F; Ciarmiello, A; Milano, A; Perri, F | 1 |
| Blay, JY; Bompas, E; Cassier, PA; Dômont, J; Gelderblom, H; Italiano, A; Kroep, JR; Maki, RG; Seddon, B; Stacchiotti, S; Thomas, D; van der Graaf, WT; Wagner, AJ | 1 |
| Blevins, M; de Vries, DJ; Eisenberg, B; Gatsonis, C; Godwin, AK; Huang, M; Melenevsky, Y; Rink, L; Sicks, J; Siegel, BA; Szot-Barnes, A; Van den Abbeele, AD; Yap, JT | 1 |
| Butrynski, J; Hornick, JL; Jagannathan, JP; Krajewski, KM; Ramaiya, NH; Shinagare, AB; Zukotynski, KA | 1 |
| Carrió-Gasset, I; Fuertes-Cabero, S; García-Garzón, JR; Lomeña-Caballero, F; Moragas-Solanes, M; Ponce-López, A; Riera-Gil, E; Soler-Peter, M; Valls-Ferrusola, E | 1 |
| Gallowitsch, HJ; Malle, P; Sorschag, M | 1 |
| Al-Saeedi, FJ; Luqmani, YA; Mathew, PM | 1 |
| Hornick, JL; Jagannathan, JP; Ramaiya, NH; Tirumani, SH | 1 |
| Bjerkehagen, B; Bruland, OS; Hole, KH; Julsrud, L; Reitan, E; Revheim, ME; Seierstad, T | 1 |
| Dimitrakopoulou-Strauss, A; Hohenberger, P; Kasper, B; Pilz, LR; Sachpekidis, C; Strauss, LG | 1 |
| Aboagye, EO; Ashek, A; Barnes, G; Cotroneo, E; Cupitt, J; Dabral, S; Dubois, O; El-Bahrawy, MA; Fang, W; Gibbs, JS; Gsell, W; He, JG; Howard, LS; Jones, H; Nguyen, QD; Pullamsetti, SS; Tomasi, G; Wang, L; Wilkins, MR; Zhao, L | 1 |
| Becker, JC; Hauschild, A; Hein, R; Helmbold, P; Kämpgen, E; Kellner, I; Leverkus, M; Mentzel, T; Mohr, P; Pföhler, C; Schadendorf, D; Schiller, M; Ströbel, P; Ugurel, S; Utikal, J | 1 |
| Gajewski, TF; Giobbie-Hurder, A; Gonzalez, R; Hodi, FS; Kim, K; O'Day, S; Van den Abbeele, AD; Weber, J; Yap, JT; Zukotynski, K | 1 |
| Chacón, M; Eleta, M; Espindola, AR; Méndez, G; Pupareli, C; Roca, E; Rojo, S | 1 |
| Boonstra, PA; Desar, I; Farag, S; Gelderblom, H; Geus-Oei, LF; Grunhagen, D; Reyners, AKL; Steeghs, N; van Coevorden, F; van der Graaf, WT | 1 |
| Alabed, YZ | 1 |
| Allard, NAE; Blijlevens, NMA; Boss, M; Gotthardt, M; Hopman, MTE; Janssen, L; Lobeek, D; Schirris, TJJ; Swaans, GJA; Timmers, S | 1 |
8 review(s) available for fluorodeoxyglucose f18 and imatinib mesylate
| Article | Year |
|---|---|
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Enzyme Inhibitors; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasms, Connective Tissue; Piperazines; Pyrimidines; Radiopharmaceuticals; Stromal Cells; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Response evaluation of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
Topics: Benzamides; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Tomography, X-Ray Computed | 2008 |
[Positron emission tomography and evaluation of response to targeted therapies].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Hypoxia; Cell Proliferation; Choline; ErbB Receptors; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lipid Metabolism; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Piperazines; Positron-Emission Tomography; Protein Biosynthesis; Protein Kinases; Pyrimidines; Radiopharmaceuticals; Receptors, Androgen; Receptors, Estrogen; TOR Serine-Threonine Kinases | 2009 |
Targeted-therapy and imaging response: a new paradigm for clinical evaluation?
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Multimodal Imaging; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
18 trial(s) available for fluorodeoxyglucose f18 and imatinib mesylate
| Article | Year |
|---|---|
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Radionuclide Imaging; Treatment Outcome | 2001 |
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Radiopharmaceuticals; Sarcoma; Survival Analysis; Tomography, Emission-Computed; Treatment Failure | 2003 |
The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Radiography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Stromal Cells; Tomography, Emission-Computed; Treatment Outcome | 2004 |
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sarcoma; Sensitivity and Specificity; Treatment Outcome | 2004 |
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Piperazines; Pyrimidines; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Longitudinal Studies; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Switzerland; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Calcitonin; Carcinoma, Medullary; Female; Fluorodeoxyglucose F18; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Mas; Pyrimidines; Survival Analysis; Thyroid Neoplasms | 2007 |
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; United States | 2007 |
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib | 2009 |
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Topics: Adult; Aged; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2009 |
Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.
Topics: Adult; Aged; Benzamides; Biological Transport; Female; Fibromatosis, Aggressive; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Male; Piperazines; Positron-Emission Tomography; Pyrimidines; Treatment Outcome | 2010 |
Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Adenoid Cystic; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Imatinib Mesylate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography, Thoracic; Radiopharmaceuticals; Remission Induction; Salivary Gland Neoplasms; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2011 |
Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Spain; Treatment Outcome | 2011 |
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biological Transport; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Genotype; Glucose Transporter Type 4; Humans; Image Processing, Computer-Assisted; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2012 |
Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.
Topics: Adult; Aged; Benzamides; Biomarkers; Female; Fibromatosis, Aggressive; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Treatment Outcome; Young Adult | 2013 |
Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Topics: Adult; Aged; Animals; Benzamides; Cell Division; Dichloroacetic Acid; Disease Models, Animal; Drug Monitoring; Familial Primary Pulmonary Hypertension; Female; Fibroblasts; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression Profiling; Glycolysis; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Indoles; Lung; Male; Middle Aged; Monocrotaline; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Sunitinib; Young Adult | 2013 |
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers; Dermatofibrosarcoma; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Oncogene Proteins, Fusion; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Female; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
29 other study(ies) available for fluorodeoxyglucose f18 and imatinib mesylate
| Article | Year |
|---|---|
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Fluorodeoxyglucose F18; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma; Stomach Neoplasms; Stromal Cells; Tomography, Emission-Computed | 2001 |
An FDG positron emission tomographic study in a case of gastrointestinal stromal tumor.
Topics: Appendiceal Neoplasms; Benzamides; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Jejunal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2003 |
F-18 FDG PET imaging in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Piperazines; Pyrimidines; Radiopharmaceuticals; Stromal Cells; Tomography, Emission-Computed; Whole-Body Counting | 2003 |
[FDG-PET and CT in gastrointestinal stromal tumor treated with imatinib].
Topics: Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Radiopharmaceuticals; Stromal Cells; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib.
Topics: Antineoplastic Agents; Benzamides; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Radiopharmaceuticals; Signal Transduction; Treatment Outcome | 2005 |
CT evaluation of gastrointestinal stromal tumors treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Data Interpretation, Statistical; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Radionuclide Imaging; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Mice; Mice, Inbred DBA; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Xenograft Model Antitumor Assays | 2005 |
Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Topics: Antineoplastic Agents; Benzamides; Fluorodeoxyglucose F18; Gamma Cameras; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2007 |
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Multivariate Analysis; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Treatment Outcome | 2007 |
[Is positron emission tomography (PET) scan useful for studying the extent of gastrointestinal stromal tumors].
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Neoplasm Proteins; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction | 2007 |
Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals | 2008 |
Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
Topics: Antineoplastic Agents; Benzamides; Biopsy, Fine-Needle; Diagnostic Imaging; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed | 2008 |
PET/CT imaging of gastrointestinal stromal tumor with calcified peritoneal implants after imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Calcinosis; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Peritoneum; Piperazines; Positron-Emission Tomography; Prostheses and Implants; Pyrimidines; Tomography, X-Ray Computed | 2008 |
Sonography of multifocal Brucella orchitis.
Topics: Adult; Antineoplastic Agents; Benzamides; Brucellosis; Contrast Media; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Hemangioma; Humans; Imatinib Mesylate; Liver Neoplasms; Magnetic Resonance Imaging; Piperazines; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography | 2008 |
The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET.
Topics: Adult; Antineoplastic Agents; Benzamides; Contrast Media; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Ultrasonography | 2008 |
Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed | 2010 |
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Enzyme Inhibitors; Everolimus; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Knockout; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Receptor, Platelet-Derived Growth Factor alpha; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST).
Topics: Benzamides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Pyrimidines; Reproducibility of Results; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Giant Cell Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Retrospective Studies; Synovitis, Pigmented Villonodular | 2012 |
Esophageal gastrointestinal stromal tumor: report of 7 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Electronic Health Records; Esophageal Neoplasms; Esophagectomy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasms, Second Primary; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Monitoring; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Assessment of tracer 99mTc(V)-DMSA uptake as a measure of tumor cell proliferation in vitro.
Topics: Benzamides; Biomarkers; Cell Line, Tumor; Cell Proliferation; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MCF-7 Cells; Neoplasms; Piperazines; Pyrimidines; Radiopharmaceuticals; S Phase; Technetium Tc 99m Dimercaptosuccinic Acid | 2013 |
Multimodal functional imaging for early response assessment in GIST patients treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Image Interpretation, Computer-Assisted; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Early Evaluation of Response Using
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2018 |
Gastrointestinal Stromal Tumor of the Prostate: Staging and Evaluation of Response to Therapy With 18F-FDG PET/CT.
Topics: Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2018 |
Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia.
Topics: Blood Glucose; Cardiovascular Diseases; Fluorodeoxyglucose F18; Glucose; Glycogen; Humans; Hyperglycemia; Imatinib Mesylate; Insulin; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Tyrosine Kinase Inhibitors | 2023 |